Supriya LifescienceNSE:SUPRIYA +4.59%76 Net Margin % is 26.84% as of Mar. 2026, which is 10% above its 10-year median of 24.41. GuruFocus rates NSE:SUPRIYA with a GF Score™ of 76/100 and a GF Value™ of ₹805.85 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 944 Biotechnology companies, Supriya Lifescience ranks better than 89.3% on this metric.
The historical rank and industry rank for Supriya Lifescience's Net Margin % or its related term are showing as below:
NSE:SUPRIYA'
s Net Margin % Range Over the Past 10 Years
Min: 14.19 Med: 24.41 Max: 32.07
Current: 25.26
NSE:SUPRIYA's Net Margin % is ranked better than 89.3% of 944
companies
in the Biotechnology industry
Industry Median: -88.815
vs NSE:SUPRIYA: 25.26
Supriya Lifescience (NSE:SUPRIYA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Supriya Lifescience Net Margin % Related Terms
Supriya Lifescience Net Margin % Historical Data
* Premium members only.
The historical data trend for Supriya Lifescience's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SUPRIYA vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Supriya Lifescience's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supriya Lifescience Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Supriya Lifescience's Net Margin % distribution charts can be found below:
* The bar in red indicates where Supriya Lifescience's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supriya Lifescience (NSE:SUPRIYA) has a Net Margin % of 26.84% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Supriya Lifescience and its competitors. This is 10% above median its historical median of 24.41. Over the past decade, Supriya Lifescience's Net Margin % has ranged from 14.19 to 32.07. According to the industry distribution chart, Supriya Lifescience ranks #101 out of 944 companies in the Biotechnology industry, placing it in the top 10.7%.
Is Supriya Lifescience's Net Margin % too high?
Supriya Lifescience's current Net Margin % of 26.84% is 10% above median its 10-year median of 24.41. Over the past 10 years, this metric has ranged from a low of 14.19 to a high of 32.07. Based on the distribution chart, Supriya Lifescience ranks #101 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Supriya Lifescience has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supriya Lifescience's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Supriya Lifescience ranks #101 out of 944 companies for Net Margin %. This places Supriya Lifescience in the top 11% of its industry — outperforming the majority of peers. Historically, Supriya Lifescience's own Net Margin % has ranged from 14.19 to 32.07 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Supriya Lifescience and its competitors. Supriya Lifescience's current Net Margin % is 26.84%, which is 10% above median its own 10-year median of 24.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supriya Lifescience stock overvalued right now?
Based on GuruFocus' analysis, Supriya Lifescience (NSE:SUPRIYA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹805.85, compared to a current price of ₹970.75 — trading 20.5% above its estimated fair value. The current Net Margin % is 26.84%, which is 10% above median its 10-year median of 24.41. Supriya Lifescience's overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Supriya Lifescience (NSE:SUPRIYA), the current Net Margin % is 26.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supriya Lifescience (NSE:SUPRIYA) Overvalued in 2026?
Based on GuruFocus' analysis, Supriya Lifescience stock appears to be overvalued.
The current stock price of ₹970.75 is trading 20.5% above its estimated GF Value™ of ₹805.85.
GuruFocus considers Supriya Lifescience to be Modestly Overvalued.
Key valuation signals for NSE:SUPRIYA:
Net Margin %: 26.84% (10% above median its 10-year median of 24.41)
GF Value™: ₹805.85 vs. price of ₹970.75 (20.5% above fair value)
No single metric tells the full story. See the NSE:SUPRIYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supriya Lifescience Ltd is a manufacturer of Active Pharmaceutical Ingredients. It is focused on diverse therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatic, and anti-allergic.
76GF Score
Get the complete analysis for NSE:SUPRIYA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SUPRIYA has been successfully added to your 
